NCT03472040Phase 2, phase 3Completed

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Study sponsor: BioCryst Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2022-04-27Actual
Enrollment · participants387Actual
Source updated2023-06-18Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.